Knight Therapeutics Inc.
GUD.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 12,209.47% | 104.39% | 57.91% | 81.14% | -350.13% |
| Total Depreciation and Amortization | -5.09% | 2.00% | 3.13% | 20.04% | -23.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -524.03% | 767.35% | -105.12% | -70.99% | 2,943.09% |
| Change in Net Operating Assets | -8.21% | 7.58% | -175.81% | 195.83% | 172.09% |
| Cash from Operations | -71.47% | 563.35% | -103.47% | 73.67% | 16.64% |
| Capital Expenditure | -45.88% | 45.47% | 25.35% | -107.81% | -91.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -94.88% | -96.96% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.53% | -4.01% | 152.11% | -601.25% | -109.27% |
| Cash from Investing | 52.56% | -1.60% | 147.53% | -1,193.40% | -105.24% |
| Total Debt Issued | -66.85% | 119.28% | 37.06% | -- | -100.00% |
| Total Debt Repaid | -162.35% | 61.63% | -203.03% | 78.41% | -261.01% |
| Issuance of Common Stock | -68.75% | 31.76% | 359.46% | -22.11% | 7.95% |
| Repurchase of Common Stock | -108.16% | -99.19% | -- | -- | -94.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -480.91% | 84.73% | -264.09% | 80.39% | -443.06% |
| Cash from Financing | -280.96% | 65.33% | -286.42% | 91.81% | -213.15% |
| Foreign Exchange rate Adjustments | 541.87% | 124.98% | -388.05% | -53.94% | 1,003.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.21% | 740.52% | -149.05% | 122.04% | -146.48% |